The US Food and Drug Administration (FDA) has approved GSK’s Nelkarmi (neladalkib) in lung cancer, marking the second product from the British pharma’s $10.6bn takeover of Nuvalent to reach market.
The accelerated approval is for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Eligible patients are those who have previously been treated with other ALK inhibitors. Roche’s Alecensa (alectinib) is one of the most widely used ALK blockers for lung cancer.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Nelkarmi’s green light was based on results from the Phase I/II ALKOVE-1 (NCT05384626) trial. For patients previously treated with Alecensa, the confirmed overall response rate (ORR) was 49%, with 52% of responses having a duration of at least a year.
GSK’s chief scientific officer, Tony Wood, said: “Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non-small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity.
“ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US.”
Before 2026, GSK had never had a medicine specifically approved for treating lung cancer in the US. Now it has two courtesy of the Nuvalent deal that closed in mid-July. A week after the deal was signed, the FDA approved Jideytro (zidesamtinib) for patients with previously treated ROS1-positive NSCLC. This marked the first drug approved from Nuvalent’s portfolio, though analysts expect Nelkarmi to reach higher commercial heights given its larger patient population.
Analysis by GlobalData’s Pharma Intelligence Centre forecasts sales of $1.2bn in 2032 for Nelkarmi, while Jideytro is expected to make $830m in the same year. Roche’s Alecensa, which generated $1.85bn in 2025, will be a main competitor to Nelkarmi.
GlobalData is the parent company of Pharmaceutical Technology.
However, Citi analysts caveated that entry into the first-line setting remains the key value driver. Any label expansion will hinge on results from the ongoing ALKAZAR Phase III study (NCT06765109) evaluating the drug in TKI-naïve patients.
